22. October 2020

New Zedira blog published about novel oral FXIIIa blockers

Zedira Logo                                                                                                                                                                          Transglutaminase-Newsletter | September 2020

Dear Transglutaminase researchers,

In our current blog Martin Stieler (Zedira’s head of structural biology) provides his perspective on an intriguing question: Can we design an oral FXIIIa blocker? Or is this going to be a “mission impossible”?

Blood coagulation factor XIII is considered being a qualified target for the development of safer anticoagulants. ZED3197 is the first drug-like compound addressing FXIIIa. Its physicochemical features predispose the compound for i.v. application in the acute care setting.

What about a new drug discovery program to design an oral compound? Curious? Then follow the link to learn more about Zedira’s concept for novel oral FXIIIa blockers.

Further, we would like to inform you about our top FXIII products for your research!


Art. No. Name Unit Price


Human blood coagulation Factor XIII-A2, recombinant
(hFXIII, A subunit, recombinantly produced in insect cells)

200 µg 370 €

Human Factor XIIIa, Thrombin activated
(hFXIIIa, recombinantly produced in insect cells)

200 µg 520 €

Human blood coagulation Factor XIII B subunit
(hFXIII B, F13B, recombinantly produced in insect cells)

200 µg 370 €

Assays and Substrates

Art. No. Name Unit Price


FXIII-Assay Substance,

10 mg
520 €

FXIII-Assay Kit
(ready to use, contains A101 and thrombin)

1 Kit
575 €

Blood coagulation FXIII-substrate-peptide F11KA

10 mg
310 €


Art. No. Name Unit Price


1,3,4,5-Tetramethyl-2[(2-oxo-propyl)thio] imidazolium chloride

10 mg
480 €

(Synonym ZED1301, site specific irreversible inhibitor of FXIII)

5 mg
480 €


Art. No. Name Unit Price


Polyclonal antibody to human factor XIII (A-subunit)

500 µg
365 €

FITC-labeled polyclonal antibody to human factor XIII (A-subunit)

200 µg
395 €
A154 Monoclonal antibody to human factor XIII (Activation Peptide, clone XTG09)

200 µg 365 €

Monoclonal antibody against crosslinked fibrin ("D-dimer")

100 µg
365 €


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Zedira publication - Features of ZED1227: The First-In-Class Tissue Transglutaminase Inhibitor Undergoing Clinical Evaluation for the Treatment of Celiac Disease
  • Dr. Falk Pharma and Zedira announce start of the phase 2b real-life study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
  • imageDr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • imagePress release: Zedira announces ISO 9001:2015 certification


  • DZG Aktuell: „Aufruf zur Teilnahme an einer weiteren Wirksamkeitsstudie mit dem Studienmedikament ZED1227“
  • imageDesign of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
  • imageMicrobial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering


  • 19th International Celiac Disease Symposium

    19.10.2022 - 22.10.2022
    Sorrento, Italy